liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up
Orebro Univ, Sweden.
Region Östergötland, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Haematology.
Kalmar Cty Hosp, Sweden.
NU Hosp Grp, Sweden.
Show others and affiliations
2020 (English)In: European Journal of Haematology, ISSN 0902-4441, E-ISSN 1600-0609, Vol. 104, no 3, p. 271-278Article in journal (Refereed) Published
Abstract [en]

Objective To explore the relative importance of risk factors, treatments, and blood counts for the occurrence of vascular complications and their impact on life expectancy in essential thrombocythemia (ET) and polycythemia vera (PV). Methods Nested case-control study within the Swedish MPN registry. From a cohort of 922 ET patients and 763 PV patients, 71 ET and 81 PV cases with vascular complications were compared with matched controls. Results Incidence of vascular complications was 2.0 and 3.4 events per 100 patient-years in ET and PV, respectively. At diagnosis, no significant risk factor differences were observed between cases and controls in neither of the diseases. At the time of vascular event, ET complication cases did not differ significantly from controls but in PV, cases had significantly higher WBCs and were to a lesser extent treated with anti-thrombotic and cytoreductive therapy. Life expectancy was significantly decreased in both ET and PV cases compared with controls. Conclusions The risk of vascular complications is high in both ET and PV, and these complications have a considerable impact on life expectancy. The protective effect of anti-thrombotic and cytoreductive therapy for vascular complications in PV underscores the importance of avoiding undertreatment.

Place, publisher, year, edition, pages
WILEY , 2020. Vol. 104, no 3, p. 271-278
Keywords [en]
essential thrombocythemia; myeloproliferative neoplasms; polycythemia vera
National Category
Hematology
Identifiers
URN: urn:nbn:se:liu:diva-164372DOI: 10.1111/ejh.13373ISI: 000513873800014PubMedID: 31863513OAI: oai:DiVA.org:liu-164372DiVA, id: diva2:1415873
Note

Funding Agencies|Regional FOU Vastra Gotaland County

Available from: 2020-03-20 Created: 2020-03-20 Last updated: 2020-03-20

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Samuelsson, Jan
By organisation
Department of Haematology
In the same journal
European Journal of Haematology
Hematology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 17 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf